Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced pseudolupus.

P J Grob, J W Müller-Schoop, M A Häcki

    Lancet (London, England)
    |July 26, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Long-term use of Venocuran, a drug for venous diseases, is linked to mitochondrial antibodies and pseudolupus symptoms. This association was not observed with other venous disease treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Immunological alterations in the ejaculate of chronic prostatitis patients: clues for autoimmunity.

    Andrologia·2003
    Same author

    Altered intracellular expression of the chemokines MIP-1alpha, MIP-1beta and IL-8 by peripheral blood CD4+ and CD8+ T cells in mild allergic asthma.

    Allergy·2003
    Same author

    [Hepatitis B virus infection: diagnosis, clinical sequelae, therapy and prevention].

    Praxis·2002
    Same author

    Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.

    Journal of acquired immune deficiency syndromes (1999)·2001
    Same author

    Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans.

    Journal of neurotrauma·2001
    Same author

    [Hepatitis C virus infection. Overview. SEVHEP (Swiss Experts on Viral Hepatitis)].

    Praxis·2000
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    See all related articles

    Area of Science:

    • Immunology
    • Pharmacology
    • Rheumatology

    Background:

    • Pseudolupus is a syndrome characterized by fever, myalgia, arthralgia, and organ inflammation.
    • Mitochondrial antibodies are present in pseudolupus patients, but not nuclear antibodies.
    • Venocuran is a medication for venous diseases containing phenopyrazone, horse-chestnut extract, and cardiac glycosides.

    Purpose of the Study:

    • To investigate the association between Venocuran use and the development of pseudolupus and mitochondrial antibodies.
    • To determine if other venous disease treatments cause similar effects.

    Main Methods:

    • Observational study of fifteen patients diagnosed with pseudolupus.
    • Analysis of medication history, focusing on Venocuran use.
    • Comparison with patients treated for venous diseases with alternative medications.

    Related Experiment Videos

    Main Results:

    • All fifteen pseudolupus patients had a history of Venocuran treatment.
    • Up to 90% of long-term Venocuran users developed mitochondrial antibodies.
    • No mitochondrial antibodies were found in patients using other venous disease drugs.
    • 30% of long-term Venocuran users reported prodromal symptoms like myalgia and arthralgia.
    • Over 10% of long-term Venocuran users developed full pseudolupus symptoms.

    Conclusions:

    • Venocuran use is strongly associated with the development of mitochondrial antibodies.
    • Long-term Venocuran use may trigger pseudolupus and its associated symptoms.
    • Alternative treatments for venous diseases do not appear to carry the same risk.